Cargando…
P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431124/ http://dx.doi.org/10.1097/01.HS9.0000848268.24972.7c |
| _version_ | 1784779966030807040 |
|---|---|
| author | Kuruvilla, J. Armand, P. Herrera, A. F. Ribrag, V. Brice, P. Thieblemont, C. Von Tresckow, B. Kim, E. Marinello, P. Chakraborty, S. Orlowski, R. Zinzani, P. L. |
| author_facet | Kuruvilla, J. Armand, P. Herrera, A. F. Ribrag, V. Brice, P. Thieblemont, C. Von Tresckow, B. Kim, E. Marinello, P. Chakraborty, S. Orlowski, R. Zinzani, P. L. |
| author_sort | Kuruvilla, J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431124 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94311242022-08-31 P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY Kuruvilla, J. Armand, P. Herrera, A. F. Ribrag, V. Brice, P. Thieblemont, C. Von Tresckow, B. Kim, E. Marinello, P. Chakraborty, S. Orlowski, R. Zinzani, P. L. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431124/ http://dx.doi.org/10.1097/01.HS9.0000848268.24972.7c Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Kuruvilla, J. Armand, P. Herrera, A. F. Ribrag, V. Brice, P. Thieblemont, C. Von Tresckow, B. Kim, E. Marinello, P. Chakraborty, S. Orlowski, R. Zinzani, P. L. P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY |
| title | P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY |
| title_full | P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY |
| title_fullStr | P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY |
| title_full_unstemmed | P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY |
| title_short | P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY |
| title_sort | p1351: characterizing allogeneic stem cell transplantation safety in patients with hematologic malignancies after pembrolizumab therapy |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431124/ http://dx.doi.org/10.1097/01.HS9.0000848268.24972.7c |
| work_keys_str_mv | AT kuruvillaj p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy AT armandp p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy AT herreraaf p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy AT ribragv p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy AT bricep p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy AT thieblemontc p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy AT vontresckowb p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy AT kime p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy AT marinellop p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy AT chakrabortys p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy AT orlowskir p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy AT zinzanipl p1351characterizingallogeneicstemcelltransplantationsafetyinpatientswithhematologicmalignanciesafterpembrolizumabtherapy |